Cranberry Attenuates Progression of Non-alcoholic Fatty Liver Disease Induced by High-Fat Diet in Mice.

Obesity is characterized by abnormal or excessive fat accumulation, which leads to the development of metabolic syndrome. Because oxidative stress is increased in obesity, antioxidants are regarded as suitable agents for preventing metabolic syndrome. Here, we examined the impact of cranberry, which contains various antioxidants, on metabolic profiles, including that during the progression of non-alcoholic fatty liver disease (NAFLD), in high-fat diet (HFD)-fed C57BL/6 mice. We observed that oxidative stress was diminished in mice that were fed HFD diets supplemented with 1 and 5% cranberry powder as compared with that in HFD-fed control mice. Notably, from 1 week after beginning the diets to the end of the study, the body weight of mice in the cranberry-treatment groups was significantly lower than that of mice in the HFD-fed control group; during the early treatment phase, cranberry suppressed the elevation of serum triglycerides; and adipocytes in the adipose tissues of cranberry-supplemented-HFD-fed mice were smaller than these cells in HFD-fed control mice. Lastly, we examined the effect of cranberry on NAFLD, which is one of the manifestations of metabolic syndrome in the liver. Histological analysis of the liver revealed that lipid-droplet formation and hepatocyte ballooning, which are key NAFLD characteristics, were both drastically decreased in cranberry-supplemented-HFD-fed mice relative to the levels in HFD-fed control mice. Our results suggest that cranberry ameliorates HFD-induced metabolic disturbances, particularly during the early treatment stage, and exhibits considerable potential for preventing the progression of NAFLD.

[1]  I. Shimomura,et al.  Oxidative Stress Inhibits Healthy Adipose Expansion Through Suppression of SREBF1-Mediated Lipogenic Pathway , 2018, Diabetes.

[2]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[3]  E. Levy,et al.  A polyphenol-rich cranberry extract reverses insulin resistance and hepatic steatosis independently of body weight loss , 2017, Molecular metabolism.

[4]  Joshua A. Salomon,et al.  Health Effects of Overweight and Obesity in 195 Countries over 25 Years. , 2017, The New England journal of medicine.

[5]  J. Lambert,et al.  Cranberry extract attenuates hepatic inflammation in high-fat-fed obese mice. , 2016, The Journal of nutritional biochemistry.

[6]  E. Tsochatzis,et al.  The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). , 2016, Metabolism: clinical and experimental.

[7]  A. Burt,et al.  Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. , 2015, Journal of hepatology.

[8]  C. Byrne,et al.  NAFLD: a multisystem disease. , 2015, Journal of hepatology.

[9]  J. H. Kim,et al.  Effects of cranberry powder on biomarkers of oxidative stress and glucose control in db/db mice , 2013, Nutrition research and practice.

[10]  P. Kris-Etherton,et al.  Cranberries and Their Bioactive Constituents in Human Health12 , 2013, Advances in nutrition.

[11]  K. Cusi,et al.  Corrigendum:The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.

[12]  Jonathan C. Cohen,et al.  Human Fatty Liver Disease: Old Questions and New Insights , 2011, Science.

[13]  L. Videla,et al.  Up-regulation of PPAR-gamma mRNA expression in the liver of obese patients: an additional reinforcing lipogenic mechanism to SREBP-1c induction. , 2011, The Journal of clinical endocrinology and metabolism.

[14]  Li Liang,et al.  Non-alcoholic fatty liver disease: An early mediator predicting metabolic syndrome in obese children? , 2011, World journal of gastroenterology.

[15]  H. Tilg,et al.  Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis , 2010, Hepatology.

[16]  B. S. Mohammed,et al.  Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity , 2009, Proceedings of the National Academy of Sciences.

[17]  C. Roberts,et al.  Oxidative stress and metabolic syndrome. , 2009, Life sciences.

[18]  K. Birkeland,et al.  Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. , 2006, Journal of hepatology.

[19]  Morihiro Matsuda,et al.  Increased oxidative stress in obesity and its impact on metabolic syndrome. , 2004, The Journal of clinical investigation.

[20]  P. Hayashi,et al.  Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis , 2003, American Journal of Gastroenterology.

[21]  H. Shimano,et al.  Absence of Sterol Regulatory Element-binding Protein-1 (SREBP-1) Ameliorates Fatty Livers but Not Obesity or Insulin Resistance inLep ob /Lep ob Mice* , 2002, The Journal of Biological Chemistry.

[22]  Joseph L Goldstein,et al.  SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. , 2002, The Journal of clinical investigation.

[23]  P. Bose,et al.  Phenol antioxidant quantity and quality in foods: fruits. , 2001, Journal of agricultural and food chemistry.

[24]  Rahul Krishnarao Patil,et al.  Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease , 2001, American Journal of Gastroenterology.

[25]  Bruce M. Spiegelman,et al.  Obesity and the Regulation of Energy Balance , 2001, Cell.

[26]  J. Flier,et al.  Obesity and insulin resistance. , 2000, The Journal of clinical investigation.

[27]  C. Day,et al.  Steatohepatitis: a tale of two "hits"? , 1998, Gastroenterology.

[28]  C. Palmeira,et al.  Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. , 2012, Free Radical Biology & Medicine.

[29]  T. Ariga The antioxidative function, preventive action on disease and utilization of proanthocyanidins , 2004, Biofactors.